HFG Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$384K Buy
418
+120
+40% +$122K 0.27% 71
2025
Q4
$320K Hold
298
0.23% 78
2025
Q3
$227K Buy
298
+2
+0.7% +$1.49K 0.17% 90
2025
Q2
$231K Hold
296
0.18% 85
2025
Q1
$244K Hold
296
0.21% 77
2024
Q4
$229K Sell
296
-63
-18% -$52.2K 0.2% 83
2024
Q3
$318K Hold
359
0.28% 65
2024
Q2
$325K Sell
359
-175
-33% -$140K 0.3% 65
2024
Q1
$415K Sell
534
-107
-17% -$76.1K 0.37% 58
2023
Q4
$374K Sell
641
-33
-5% -$19.3K 0.36% 56
2023
Q3
$362K Buy
674
+122
+22% +$62.9K 0.4% 59
2023
Q2
$259K Sell
552
-50
-8% -$21K 0.27% 74
2023
Q1
$207K Hold
602
0.24% 82
2022
Q4
$220K Buy
+602
New +$213K 0.26% 81

Other funds holding LLY

HFG Advisors's LLY Position: Q1 2026 in Review

HFG Advisors increased its Eli Lilly (LLY) stake by 40% in Q1 2026, buying an estimated $122K and bringing the position to 418 shares worth $384K. The position accounts for 0.27% of the portfolio, ranked #71.

HFG Advisors first reported a position in LLY in Q4 2022 and has held it in 14 quarters since. The position peaked at $415K in Q1 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • HFG Advisors held 418 shares of Eli Lilly worth $384K as of Q1 2026.
  • HFG Advisors bought 120 Eli Lilly shares in Q1 2026, an estimated $122K.
  • Eli Lilly made up 0.27% of HFG Advisors's portfolio in Q1 2026, its #71 holding.
  • HFG Advisors first reported a position in Eli Lilly in Q4 2022 and has held it in 14 quarters since.
  • HFG Advisors's Eli Lilly position peaked at $415K in Q1 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on HFG Advisors's 13F filing for Q1 2026, filed 8 May 2026.